Background pattern of a brain with neural connections

Team Ashton

PD-BUILD: Biomarker Utilization, Innovation, and Laboratory-to-Deployment

2026-Present

This project will develop and validate a series of ultrasensitive multiplex immunoassays to quantify protein targets in plasma and cerebrospinal fluid, enabling broad evaluation across the Parkinson’s disease research. Development will be carried out collaboratively across biomarker development groups, and where appropriate, novel antibody strategies will be deployed, with analytical performance established and cross-validated to ensure robustness and reproducibility. The resulting immunoassays will be benchmarked using well-characterized datasets to assess their biological relevance. Upon validation, the panels will be widely available—either as commercial research-use only kits with a track toward In Vitro Diagnostic development.

Tags
AntibodyBiomarker assayBiomarker validationPlasma

Contributions

Stay tuned—this is where the team’s scientific contributions will be shared.

Accolades

Check back soon to see how this team is being recognized.

In the News

Aligning Science Across Parkinson’s and The Michael J. Fox Foundation Expand Global Research Initiative with $261M Investment Toward Personalized Treatments

Aligning Science Across Parkinson’s and The Michael J. Fox Foundation Expand Global Research Initiative with $261M Investment Toward Personalized Treatments

04/28/2026 — Today, Aligning Science Across Parkinson’s (ASAP), in partnership with The Michael J. Fox Foundation for Parkinson’s Research (MJFF), announced $261 million in new grant funding for the Collaborative Research Network (CRN) to map the biological blueprint of Parkinson’s disease and build a standardized toolkit of global research resources that are needed to turn discoveries into treatments.

Our Research Teams

Members of the CRN work diligently to advance our understanding of Parkinson’s disease. Learn more about recent CRN discoveries and achievements.